Complement Mediated Diseases
Stories
-
Novartis registers Phase 3b roll-over extension study of iptacopan
The study plans to enroll 36 participants and is scheduled to start on November 16, 2026. It aims to assess the long-term safety, tolerability, and efficacy of iptacopan in patients with complement mediated diseases.